The Phase 2 ACT-AD trial (NCT04491006) in mild-to-moderate Alzheimers disease failed its primary endpoint in June 2022
Cascone T, William Jr WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy M, Carter BW, Federico L, Reuben A, Khan AW, Dejima H, Cruz AF, Parra ER, Solis LM, Fujimoto J, Tran H, Moran C, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein Jr G, Le X, Zhang J, Skoulidis F, Kurie J, Altan M, Lu C, Glisson B, Byers LA, Elamin Y, Mehran RJ, Rice DC, Walsh G, Hofstetter WL, Roth JA, Antonoff M, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison J, Futreal A, Wargo JA, Wistuba II, Swisher SG , Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B
Blue Copper Peptide Serum: The Ultimate EGF Repair & Anti-Aging Concentrate 1
Insulin-sensitizing peptides and metformin for combined metabolic and reproductive benefit
How TENXIMA 3D GLOW Works TENXIMA 3D GLOW works through a multi-pathway mechanism that targets the root causes of pigmentation and skin dullness